top of page
  • Recruiting

NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)

Updated: Jun 16, 2022

NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)

impede-study

Isatuximab in combination with elotuzumab, pomalidomide, and dexamethasone (Isa-EPD)


This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.


Sponsor

Medical College of Wisconsin

 

ClinicalTrials.gov Identifier: NCT04835129

Official Title: A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

First Posted: April 8, 2021


Click here to see details on ClinicalTrials.gov

 



 

Drug: Isatuximab (for run-in portion)

Drug: Isatuximab (for expansion)

Drug: Pomalidomide

Drug: Elotuzumab

Drug: Dexamethasone

 

Locations

United States, Wisconsin

Froedtert Hospital & the Medical College of Wisconsin

Bình luận


Posts Archive
bottom of page